• Skip to primary navigation
  • Skip to main content

National Forum

  • Home
  • About
    • Advisory Leadership Council
    • Board of Directors
    • History
    • National Forum Awards
    • Team
    • Support
  • Collaborations
    • Counter Cholesterol™
    • Million Hearts®
    • Move with the Mayor™
    • Signature Reports
    • Stronger Hearts™
    • Value & Access
      • Value & Innovation Forum
    • World Heart Day
  • Events
    • Heart Failure Roundtable
    • 2020 Annual Meeting
    • Value & Innovation Forum
    • Meeting Archives
      • 2020 Mid-Year Meeting
      • 2019 Annual Meeting
      • 2019 Virtual Convening on Stroke
      • 2019 Mid-Year Member Meeting
      • 2018 Annual Meeting
      • 2018 Mid Year Meeting
  • Members
    • Membership
  • Newsroom
  • Search Toggle
  • Skip to content

Value & Access Steering Committee & Partners Provide Consensus Feedback on ICER Draft Scope of High Cholesterol Treatments

Posted on 07.24.20

The National Forum’s Value & Access Initiative Steering Committee and partners engaged in the value & access space provided consensus feedback on the Institute for Clinical and Economic Review (ICER)’s draft scope of the assessment of the comparative clinical effectiveness and value of inclisiran (Novartis) and bempedoic acid (Nexletol™, Esperion Therapeutics, Inc.) for treatment of high cholesterol in the setting of heterozygous familial hypercholesterolemia or secondary prevention of ASCVD.

Categories: In the News, Value & Access

1150 Connecticut Ave., NW, Suite 300, Washington, DC 20036 Phone: (866) 894-3500
Copyright © 2021 National Forum for Heart Disease & Stroke Prevention. All Rights Reserved
  • Facebook
  • Twitter